Abstract 49P
Background
Numb is a protein involved in asymmetric cell division determining cell fate across various research fields such as developmental neurobiology and cancer biology; however, its role remains poorly understood regarding brain metastases formation specifically within lung adenocarcinoma (LUAD).
Methods
In our previous study, five potential biomarkers for brain metastasis (BM) were identified using proteomic comparison of brain metastatic H1975-BrM cells and parent H1975 cells. We utilized the Cancer Genome Atlas Program (TCGA) database to analyze five genes expression at the level of mRNA in LUAD. Univariate and multivariate analyses were used to select independent risk factors that affect the prognosis of LUAD, and a nomogram model was established. The relationship between NUMB expression and LUAD immune infiltration was analyzed using TIMER, GEPIA database and TCGA data sets. In addition, clinical validation was performed using immunohistochemical (IHC) staining of lung tumor tissue from patients (n = 50) and investigated the relationship between NUMB and clinicopathology and prognosis in LUAD. The q-PCR and Western-blot assays were used to validate the expression of NUMB in vitro.
Results
After analyzing the prognostic value of those 5 differentially expressed genes, NUMB was the only gene associated with multiple prognostic indicators in LUAD patients using TCGA public database. Analysis of GEPIA datasets revealed that high NUMB expression in LUAD tissues correlates with poor patient survival. Multivariate analysis showed that Pathologic T stage, N stage, and high level of NUMB protein were independent prognostic factors of overall survival in patients with LUAD. These factors were used to construct the nomogram model. The analysis of TIMER, GEPIA database and TCGA data sets showed that the expression level of NUMB was negatively correlated with B cells, NK cells and Cytotoxic cells. Furthermore, NUMB was highly expressed in brain metastatic H1975-BrM cell line.
Conclusions
Our findings demonstrate that NUMB serves as an independent potential prognostic biomarker implicated not only in immune infiltration of LUAD, but also closely correlates with BM development.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
152P - Nanopore sequencing of cfDNA captures key copy number alterations in lung adenocarcinoma: A non-invasive approach for prognosis, therapy, and subtyping
Presenter: Khashayar Roohollahi
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - Discovery of new BRCA1/2 mutations not described in the international breast consortium
Presenter: Wala Ben Kridis
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - Alternative splicing in non-small cell lung cancer evolution
Presenter: Michelle Leung
Session: Cocktail & Poster Display session
Resources:
Abstract
155TiP - Exploring mechanisms of action and resistance to innovative therapeutic drugs: UNLOCK program
Presenter: Julieta Rodriguez
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - Therapeutic potential of B7-H3 targeting in pediatric neuroblastoma
Presenter: Caroline E Nunes-Xavier
Session: Cocktail & Poster Display session
Resources:
Abstract
158P - E-JIB-04: An epigenetic targeted therapy for ovarian cancer with MECOM amplification
Presenter: Ibha Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - The impact of kisspeptin pre-treatment towards temozolomide resistance mechanisms and associated differently expressed proteins (DEPs) in human glioblastoma cells
Presenter: Isra Sati
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - Clinical observation and immune effects of high-intensity focused ultrasound (HIFU) in the treatment of liver metastasis in colorectal cancer
Presenter: Shasha Wang
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - Early phase cancer clinical trials: A viable treatment option for patients?
Presenter: Rhona Dawson
Session: Cocktail & Poster Display session
Resources:
Abstract
162P - Tailoring patient molecular selection for novel anti-MET therapies
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract